Abbott Faces Calls For Compulsory License For Norvis

Law360, New York (May 13, 2004, 12:00 AM EDT) -- Abbott Laboratories’ nearly fivefold increase on its AIDS drug Norvis has prompted calls from government officials for a compulsory license for a generic version of the drug before its patent expiration, the Wall Street Journal reported.

In December, Abbott Labs raised the wholesale price for a month's worth of the protease inhibitor Norvir, widely used in small doses to boost the potency of some AIDS combination-drug therapies, to $265 from $54.

The move caused an avalanche of protests from AIDS activists, who have demanded a public...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.